Abstract
Purpose :
To compare the therapeutic effect of topical adiponectin (ADP)-derived short peptides and globular adiponectin in a mouse model of experimental dry eye (EDE).
Methods :
EDE was created by desiccating stress in 6- to 8-weeks old female C57BL/6 mice. Eye drops containing 0.01% globular ADP, 0.01% ADP peptide 399 or 355, or balanced salt solution (BSS) were applied. Tear volume, tear film break-up time (TBUT), and corneal staining scores were measured at 5 and 10 days after treatment. Levels of IL-1β, IL-6, IFN-γ, CXCL-9, and CXCL-10 were measured in the conjunctiva using a multiplex immunobead assay at 10 days. Flow cytometric analysis for CD4+CCR5+ T cells was also performed.
Results :
The globular ADP and both ADP-derived short peptide groups showed a significant improvement in tear volume, TBUT, corneal staining scores, and CD4+CCR5+ T cell infiltration compared with the EDE control and BSS-treated groups. Significantly decreased levels of IL-1β, CXCL-9, and CXCL-10 were observed in the globular ADP group compared with the EDE control. The 0.01% ADP peptide 399 and 355 treatment groups showed significantly decreased levels of IFN-γ, IL-1β, IL-6, CXCL-9, and CXCL-10 compared with the EDE control group and IFN-γ, IL-6, and CXCL-9 compared with the BSS group. However, there were no significant differences in all clinical and experimental parameters among the globular ADP and both ADP-derived short peptide groups.
Conclusions :
Topical application of ADP-derived peptides could improve clinical signs and decrease inflammation of the ocular surface of EDE, and the effects were similar to those of globular ADP.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.